How many 8-K filings has Emergent Biosolutions Inc. filed?

Emergent Biosolutions Inc. (EBS) has 39 8-K (Current Event Report) filings on record, spanning Jan 2024 to Dec 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Emergent Biosolutions Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Emergent Biosolutions Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Emergent Biosolutions Inc. (EBS) — 8-K Filings

All 8-K filings from Emergent Biosolutions Inc.. Browse 39 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (39)

Emergent BioSolutions Files 8-K on Dec 12, 2025 — Dec 12, 2025 Risk: low
Emergent BioSolutions Inc. filed an 8-K on December 12, 2025, reporting on events that occurred on the same date. The filing primarily concerns financial statem
8-K Filing — Nov 12, 2025
Emergent BioSolutions Files 8-K on Financials — Oct 29, 2025 Risk: medium
Emergent BioSolutions Inc. filed an 8-K on October 29, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation
Emergent BioSolutions Files 8-K on Material Agreement — Sep 11, 2025 Risk: medium
Emergent BioSolutions Inc. filed an 8-K on September 11, 2025, reporting on events that occurred on September 5, 2025. The filing indicates the entry into a mat
Emergent BioSolutions Files 8-K — Sep 5, 2025 Risk: low
Emergent BioSolutions Inc. filed an 8-K on September 5, 2025, reporting an event on September 2, 2025. The filing is a current report under the Securities Excha
Emergent BioSolutions Files 8-K on Financials — Aug 6, 2025 Risk: medium
Emergent BioSolutions Inc. filed an 8-K on August 6, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation F
Emergent BioSolutions Files 8-K — Jun 24, 2025 Risk: low
Emergent BioSolutions Inc. filed an 8-K on June 24, 2025, reporting an event on June 23, 2025. The filing primarily concerns "Other Events" and "Financial State
Emergent BioSolutions Files 8-K — May 23, 2025 Risk: low
Emergent BioSolutions Inc. filed an 8-K on May 23, 2025, reporting other events and financial statements. The filing does not contain specific details about the
Emergent BioSolutions Files 8-K on Financials — May 7, 2025 Risk: low
Emergent BioSolutions Inc. filed an 8-K on May 7, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD d
Emergent BioSolutions Files 8-K on Shareholder Votes & Financials — May 6, 2025 Risk: low
Emergent BioSolutions Inc. filed an 8-K on May 6, 2025, reporting on matters submitted to a vote of security holders and financial statements as of April 30, 20
Emergent BioSolutions Files 8-K — Mar 31, 2025 Risk: low
Emergent BioSolutions Inc. filed an 8-K on March 31, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing details the company's pr
Emergent BioSolutions Sells Generics Portfolio for $300M — Mar 24, 2025 Risk: medium
Emergent BioSolutions Inc. announced on March 19, 2025, that it has entered into a definitive agreement to sell its portfolio of branded generics and over-the-c
Emergent BioSolutions Files 8-K — Mar 10, 2025 Risk: low
Emergent BioSolutions Inc. filed an 8-K on March 10, 2025, to report on various events. The filing includes information related to Regulation FD Disclosure, Oth
Emergent BioSolutions Files 8-K on Financials — Mar 3, 2025 Risk: medium
Emergent BioSolutions Inc. filed an 8-K on March 3, 2025, to report on its results of operations and financial condition. The filing also includes Regulation FD
Emergent BioSolutions Files 8-K — Jan 15, 2025 Risk: low
Emergent BioSolutions Inc. filed an 8-K on January 15, 2025, reporting on Regulation FD disclosures and financial statements. The filing details the company's p
Emergent BioSolutions Files 8-K — Jan 14, 2025 Risk: low
Emergent BioSolutions Inc. filed an 8-K on January 14, 2025, to report other events and financial statements. The filing does not contain specific details about
Emergent BioSolutions Files 8-K for Financials — Jan 8, 2025 Risk: low
Emergent BioSolutions Inc. filed an 8-K on January 8, 2025, reporting an event on December 12, 2024. The filing is primarily for financial statements and exhibi
Emergent BioSolutions Files 8-K on Financials — Nov 6, 2024 Risk: medium
Emergent BioSolutions Inc. filed an 8-K on November 6, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation
Emergent BioSolutions Announces Board and Executive Changes — Oct 4, 2024 Risk: medium
Emergent BioSolutions Inc. announced on October 2, 2024, changes in its board of directors and executive compensation. The filing details the departure of certa
Emergent BioSolutions Files 8-K: Material Agreement & Financial Update — Oct 2, 2024 Risk: medium
Emergent BioSolutions Inc. reported on September 30, 2024, that it entered into a material definitive agreement. The company also disclosed its results of opera
Emergent BioSolutions Reports Unregistered Equity Sales — Sep 17, 2024 Risk: medium
Emergent BioSolutions Inc. filed an 8-K on September 17, 2024, reporting on unregistered sales of equity securities. The filing details transactions related to
Emergent BioSolutions Files 8-K on Agreements and Obligations — Sep 3, 2024 Risk: medium
Emergent BioSolutions Inc. filed an 8-K on August 30, 2024, reporting the entry into and termination of material definitive agreements. The company also disclos
Emergent BioSolutions Files 8-K — Aug 30, 2024 Risk: medium
Emergent BioSolutions Inc. filed an 8-K on August 30, 2024, reporting events as of August 29, 2024. The filing includes information related to Regulation FD Dis
Emergent BioSolutions Files 8-K — Aug 20, 2024 Risk: low
Emergent BioSolutions Inc. filed an 8-K on August 20, 2024, reporting on various events. The filing includes information related to Regulation FD disclosures, o
Emergent BioSolutions Files 8-K on Financials — Aug 6, 2024 Risk: medium
Emergent BioSolutions Inc. filed an 8-K on August 6, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation F
Emergent BioSolutions Enters Material Definitive Agreement — Jul 31, 2024 Risk: medium
Emergent BioSolutions Inc. announced on July 31, 2024, that it has entered into a material definitive agreement. The company also disclosed information related
Emergent BioSolutions Appoints New Directors, Adjusts CFO Compensation — Jul 30, 2024 Risk: medium
Emergent BioSolutions Inc. announced on July 30, 2024, changes in its board of directors and executive compensation. The company elected two new directors, Robe
Emergent BioSolutions Shuffles CFO, Adds Directors — Jul 12, 2024 Risk: medium
Emergent BioSolutions Inc. announced on July 11, 2024, the departure of its Chief Financial Officer, Richard S. Lindahl, effective July 12, 2024. The company al
Emergent BioSolutions Sells Device Unit for $100M — Jul 8, 2024 Risk: medium
Emergent BioSolutions Inc. announced on July 3, 2024, that it has entered into a definitive agreement to sell its device and services business to Fresenius Kabi
Emergent BioSolutions Enters Material Definitive Agreement — Jul 2, 2024 Risk: medium
Emergent BioSolutions Inc. announced on June 28, 2024, that it entered into a material definitive agreement. The company also disclosed information related to R
Emergent BioSolutions Files 8-K — Jun 20, 2024 Risk: low
Emergent BioSolutions Inc. filed an 8-K on June 20, 2024, to report on other events and financial statements. The filing does not contain specific details about
Emergent BioSolutions Shuffles Top Leadership — May 29, 2024 Risk: medium
Emergent BioSolutions Inc. announced on May 23, 2024, the departure of its Chief Financial Officer, Richard S. Lindahl, effective immediately. The company also
Emergent BioSolutions Files 8-K on Exit Costs — May 1, 2024 Risk: medium
Emergent BioSolutions Inc. filed an 8-K on May 1, 2024, to report on cost-associated exit or disposal activities. The filing also includes Regulation FD disclos
Emergent BioSolutions Enters Material Definitive Agreement — Apr 30, 2024 Risk: medium
Emergent BioSolutions Inc. announced on April 29, 2024, that it entered into a Material Definitive Agreement. This agreement creates a direct financial obligati
Emergent BioSolutions Appoints Interim CEO, Starts Permanent Search — Apr 26, 2024 Risk: medium
Emergent BioSolutions Inc. announced on April 23, 2024, the appointment of Robert G. (Bob) Kramer as Interim Chief Executive Officer, succeeding Paul F. McKinne
Emergent BioSolutions Files 8-K on Agreements and Financials — Mar 6, 2024 Risk: medium
Emergent BioSolutions Inc. filed an 8-K on February 29, 2024, reporting on a material definitive agreement and its financial condition. The filing also disclose
Emergent BioSolutions 8-K: Officer Changes & Disclosure — Feb 21, 2024 Risk: medium
Emergent BioSolutions Inc. filed an 8-K on February 21, 2024, reporting an event that occurred on February 20, 2024. The filing pertains to Item 5.02, "Departur
Emergent BioSolutions Files Routine 8-K on Jan 9 Event — Jan 11, 2024
Emergent BioSolutions Inc. filed an 8-K on January 11, 2024, reporting an event that occurred on January 9, 2024. This filing is a routine disclosure under 'Oth
Emergent BioSolutions Files 8-K for Reg FD Disclosure — Jan 9, 2024
Emergent BioSolutions Inc. filed an 8-K on January 9, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. This filing indicates th

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX